UK Begins First Human Trials for New Ebola Vaccine Amid Deadly DRC Outbreak
UK initiates human trials for a new Ebola vaccine targeting the Bundibugyo strain, amid a deadly outbreak in the Democratic Republic of Congo.
POLICY WIRE — Oxford, UK — A volunteer has been administered the first dose of a newly developed vaccine targeting the Bundibugyo strain of Ebola, marking the initiation of human trials in the UK. The trial, conducted by Oxford University, aims to address the ongoing deadly outbreak in the Democratic Republic of Congo (DRC).
The Ebola outbreak, which began in May, has claimed over 1,000 lives in the DRC and Uganda, according to the World Health Organization (WHO). In response, researchers and health organizations have accelerated efforts to develop a vaccine or treatment for this relatively rare strain.
“A volunteer was injected on Friday with the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola driving a deadly outbreak in the Democratic Republic of Congo (DRC), Oxford University said,” stated the university in an official release.
The trial’s commencement underscores the urgency and collaborative efforts in the global health community to combat the Ebola virus. The vaccine’s development has been a priority given the severity — and rapid spread of the current outbreak.
The WHO and other international health bodies are closely monitoring the trial’s progress, hoping for a breakthrough that could help control the outbreak and prevent further loss of life. The vaccine, if proven effective, could be a critical tool in the fight against Ebola.
Reporting by Policy-Wire (PW)
